ArticlePloS one2025
Exosomes combined with extra virgin olive oil reduces lipogenesis, oxidative stress, and inflammation in non-alcoholic fatty liver disease model.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mesenchymal stem cells and extracellular vesicles for MAFLD: from biological mechanisms to translational prospects.Stem cell research & therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In response to high-fat-diet, excessive lipid accumulation in the liver results in chronic damage and inflammation. Olive oil has been studied for its health beneficial effects in hyperlipidemia (mainly has lipids lowering and antioxidative potential) while mesenchymal stem cells derived exosomes (MSCs-Exo) are investigated mainly for their tissue regenerative and anti-inflammatory potential. In the present study we aimed to combine the beneficial effects of Extra Virgin Olive Oil (EVOO) and MSCs-Exo on a model of high-fat-diet induced Non-Alcoholic Fatty Liver Disease (NAFLD, which still lacks effective treatment protocols) and detect whether an improved response could be achieved from this combination. Sprague Dawley rats (n = 40) were randomly assigned to five groups (n = 8/group), control, hyperlipidemia (HL), HL+EVOO, HL + Exo and HL + Exo+EVOO. Our results show that better antihyperlipidemic effects were obtained in the combined group receiving Exo+EVOO treatment more than using EVOO or MSCs-Exo alone. This was achieved by improving plasma lipids profile, improving antioxidants stores and reducing lipid peroxidation, no change in liver function parameters which was confirmed also by the histopathological examination of the liver where a preserved normal liver architecture. To further elucidate the mechanisms involved, the gene expression levels of lipogenesis (SREBP-1c, ACC, FAS, GPAT3, SCD1, and FSP27), inflammation (IL-1β, TNF-α, IL-6, IL-18, CCL20, and NF-κB), lipid peroxidation (CPT1A, ACOX1) and PPAR pathway (PPARα, PPARγ) were all normalized. This indicates that combined Exo+EVOO harnessed the benefits of both, and this was much better in treating hyperlipidemia and NAFLD and warrants prospects for approaches that could be adopted to treat NAFLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.